- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02532335
Obeticholic Acid in Morbidly Obese Patients and Healthy Volunteers (OCAPUSH)
Study of the Effects of Obeticholic Acid on Farnesoid X Receptor Expression in Jejunum and on Gut Microbiota in Morbidly Obese Patients and Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Hanns-Ulrich Marschall, MD, PhD, MSc
- Phone Number: +46708774073
- Email: hanns-ulrich.marschall@gu.se
Study Locations
-
-
-
Göteborg, Sweden, 411 31
- Recruiting
- Hanns-Ulrich Marschall
-
Contact:
- Hanns-Ulrich Marschall
- Phone Number: +4670774073
- Email: hanns-ulrich.marschall@gu.se
-
Principal Investigator:
- Hanns-Ulrich Marschall, MD, PhD
-
Göteborg, Sweden
- Enrolling by invitation
- Sahlgrenska Academy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Morbid obesity awaiting gastric bypass surgery, ≥35 kg/m2
Male subjects, pre-, and post-menopausal female subjects
Women of childbearing potential can only be included if a safe and reliable contraception is used, e.g., oral contraceptives
Patients eligible to laparoscopic bariatric surgery
Patients must give their signed and dated written consent to participate in this study based on written information of all pertinent aspects of the trial provided at least 24 hours before undertaking any trial related activity.
Exclusion Criteria:
Chronic liver disease other than NAFLD (viral hepatitis, autoimmune liver disease, hemochromatosis, homozygous alpha1-antitrypsin deficiency and Wilson disease)
Previous gastric or small bowel surgery
Inflammatory bowel disease
Uncontrolled diabetes mellitus (fasting blood glucose >6.7 mmol/L), hypothyroidism or hyperthyroidism, or other significant endocrine disease.
Pregnancy. A urine pregnancy test will be performed the day before start of medication. Women of childbearing potential can only be included if a safe and reliable contraception is used, e.g., oral contraceptives.
Elevations of transaminases (ALAT/ASAT) or alkaline phosphatase or bilirubin above 2xULN (upper limit of normal) the day before start of medication.
Other serious disease, including depressive disorders treated by medication
Patients who will not comply with the protocol.
Hypothyroidism, unless the subject is clinically euthyroid, receiving a stable dose thyroid hormone replacement therapy and serum TSH is within the normal range.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Morbid Obesity OCA
Obeticholic acid 25 mg/day in three weeks
|
active drug
Other Names:
|
Placebo Comparator: Morbid Obesity Placebo
Obeticholic acid 25 mg/day matching placebo in three weeks
|
active drug
Other Names:
matching placebo
Other Names:
|
Active Comparator: Healthy Volunteers OCA
Obeticholic acid Obeticholic acid 25 mg/day in three weeks
|
active drug
Other Names:
|
Placebo Comparator: Healthy volunteers Placebo
Obeticholic acid 25 mg/day matching placebo in three weeks
|
active drug
Other Names:
matching placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ChIP-assay in biopsies as a measure of Activation of FXR-dependent genes in small intestine
Time Frame: Three weeks
|
ChIP-assay in biopsies
|
Three weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Shot-gun metagenomics as a measure of Impact of FXR activation on gut microbiota
Time Frame: Three weeks
|
Shot-gun metagenomics
|
Three weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hanns-Ulrich Marschall, Sahlgrenska University Hospital, Sweden
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OCAPUSH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Obeticholic acid
-
GlaxoSmithKlineCompletedPruritusUnited States
-
National Institute of Diabetes and Digestive and...CompletedNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)United States
-
Abhimanyu GargCompletedFamilial Partial LipodystrophyUnited States
-
GlaxoSmithKlineCompletedCholestasisUnited Kingdom
-
Nanjing Chia-tai Tianqing PharmaceuticalRecruitingPrimary Biliary CholangitisChina
-
Intercept PharmaceuticalsSyneos Health; Global PBC Study Group; Target RWE; UK PBC Study GroupWithdrawnPrimary Biliary CholangitisUnited States
-
Intercept PharmaceuticalsCompletedNonalcoholic Steatohepatitis | Compensated CirrhosisUnited States, Spain, France, Australia, New Zealand, Puerto Rico, Germany, Canada, United Kingdom, Hungary, Poland, Ukraine
-
Intercept PharmaceuticalsCompletedPrimary Sclerosing Cholangitis (PSC)United States, Italy
-
Intercept PharmaceuticalsSyneos Health; Global PBC Study Group; Target RWE; UK PBC GroupCompletedPrimary Biliary CholangitisUnited States
-
Intercept PharmaceuticalsTerminatedNon Alcoholic Steatohepatitis (NASH)United States, Finland, France, Spain, United Kingdom, Israel, Austria, Italy, Denmark, Germany, Belgium, Switzerland, Puerto Rico, Poland, Australia, Sweden, Serbia, New Zealand, Canada, Hungary, Portugal